Pharmaceutical companies by P/B ratio
Share price divided by book value per share: what the market pays for each dollar of shareholders' equity on the balance sheet.
Travere Therapeutics leads the 39 pharmaceutical companies ranked by P/B ratio, at 213, ahead of Arrowhead Pharmaceuticals (121) and Rhythm Pharmaceuticals (93.8). Figures as of 19 Nov 2026, 01:27 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 39
- First
- Travere Therapeutics213
- Median
- 6.8
- Combined market value
- HUF 1699.24T
- Countries
- 10
- Not ranked
- 22no P/B ratio on file
Market values as of .
All countries▾
All sectors▾
Pharmaceuticals▾
| # | Company | P/B ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Travere TherapeuticsTVTX · Health Care | 213 | HUF 1.62T | HUF 16,874.76 | 1.68% down | 44% up | ||
| 2 | Arrowhead PharmaceuticalsARWR · Health Care | 121 | HUF 2.05T | HUF 14,479.92 | 0.28% up | 10% up | ||
| 3 | Rhythm PharmaceuticalsRYTM · Health Care | 93.8 | HUF 2.77T | HUF 39,983.51 | 2.08% up | 13% up | ||
| 4 | Axsome TherapeuticsAXSM · Health Care | 66.8 | HUF 2.37T | HUF 45,008.32 | 1.43% down | 7% down | ||
| 5 | InsmedINSM · Health Care | 36.2 | HUF 8.83T | HUF 40,238.78 | 1.69% down | 40% down | ||
| 6 | Eli LillyLLY · Health Care | 30.6 | HUF 413.7T | HUF 464,442.22 | 2.32% down | 35% up | ||
| 7 | TG TherapeuticsTGTX · Health Care | 16.2 | HUF 3.36T | HUF 22,208.58 | 5.44% up | 107% up | ||
| 8 | Summit TherapeuticsSMMT · Health Care | 14.9 | HUF 2.82T | HUF 3,526.77 | 1.59% down | 36% down | ||
| 9 | Madrigal PharmaceuticalsMDGL · Health Care | 14.7 | HUF 3.11T | HUF 133,708.30 | 5.67% down | 24% down | ||
| 10 | Amneal PharmaceuticalsAMRX · Health Care | 14.3 | HUF 2.56T | HUF 7,349.12 | 3.60% up | 83% up | ||
| 11 | Ionis PharmaceuticalsIONS · Health Care | 11.6 | HUF 1.53T | HUF 9,199.84 | 1.59% up | 64% down | ||
| 12 | Cogent BiosciencesCOGT · Health Care | 10.7 | HUF 1.63T | HUF 9,340.91 | 0.14% down | 20% down | ||
| 13 | ZoetisZTS · Health Care | 10.6 | HUF 11.68T | HUF 28,741.51 | 2.50% up | 29% down | ||
| 14 | Spyre TherapeuticsSYRE · Health Care | 10.1 | HUF 3.24T | HUF 34,078.69 | 8.15% up | 286% up | ||
| 15 | Corcept TherapeuticsCORT · Health Care | 8.9 | HUF 2.49T | HUF 22,769.51 | 3.25% down | 8% down | ||
| 16 | Johnson & JohnsonJNJ · Health Care | 8.1 | HUF 220.5T | HUF 91,595.29 | 2.15% down | 38% up | ||
| 17 | Belite BioBLTE · Health Care | 8.0 | HUF 2.13T | HUF 52,475.00 | 0.94% down | 31% up | ||
| 18 | Protagonist TherapeuticsPTGX · Health Care | 7.6 | HUF 2.79T | HUF 42,710.88 | 2.00% up | 46% up | ||
| 19 | Merck & CoMRK · Health Care | 7.6 | HUF 114.09T | HUF 46,277.96 | 3.90% down | 51% up | ||
| 20 | Praxis Precision MedicinesPRAX · Health Care | 6.8 | HUF 2.87T | HUF 102,508.13 | 0.04% up | 61% up | ||
| 21 | VeradermicsMANE · Health Care | 6.6 | HUF 1.77T | HUF 41,938.35 | 0.62% down | 233% up | ||
| 22 | Vertex PharmaceuticalsVRTX · Health Care | 6.5 | HUF 45.68T | HUF 180,184.44 | 0.42% up | 27% up | ||
| 23 | Ligand PharmaceuticalsLGND · Health Care | 6.2 | HUF 2.01T | HUF 100,331.61 | 1.67% up | 43% up | ||
| 24 | Alnylam PharmaceuticalsALNY · Health Care | 5.5 | HUF 6.72T | HUF 50,180.92 | 4.54% down | 66% down | ||
| 25 | Oruka TherapeuticsORKA · Health Care | 5.4 | HUF 2.18T | HUF 32,157.44 | 0.60% down | 241% up | ||
| 26 | ErascaERAS · Health Care | 5.3 | HUF 1.62T | HUF 4,621.75 | 0.94% down | 403% up | ||
| 27 | Bristol-Myers SquibbBMY · Health Care | 5.2 | HUF 40.89T | HUF 20,005.19 | 2.92% down | 34% up | ||
| 28 | Royalty PharmaRPRX · Health Care | 4.5 | HUF 13.26T | HUF 23,065.09 | 0.01% down | 78% up | ||
| 29 | Definium TherapeuticsDFTX · Health Care | 4.1 | HUF 1.34T | HUF 9,780.91 | 0.88% down | 169% up | ||
| 30 | United TherapeuticsUTHR · Health Care | 3.9 | HUF 8.26T | HUF 193,918.69 | 1.16% down | 23% up | ||
| 31 | Dianthus TherapeuticsDNTH · Health Care | 3.8 | HUF 1.59T | HUF 28,207.45 | 3.45% down | 113% up | ||
| 32 | Abbott LaboratoriesABT · Health Care | 3.5 | HUF 60.78T | HUF 35,093.06 | 0.22% down | 17% down | ||
| 33 | Regeneron PharmaceuticalsREGN · Health Care | 2.8 | HUF 32.85T | HUF 317,587.45 | 1.28% down | 36% up | ||
| 34 | Edgewise TherapeuticsEWTX · Health Care | 2.8 | HUF 1.52T | HUF 13,895.48 | 1.59% down | 88% up | ||
| 35 | Legend BiotechLEGN · Health Care | 2.5 | HUF 1.06T | HUF 5,458.10 | 0.87% up | 42% down | ||
| 36 | Elanco Animal HealthELAN · Health Care | 2.0 | HUF 4.48T | HUF 8,968.08 | 3.29% up | 20% up | ||
| 37 | BioMarin PharmaceuticalBMRN · Health Care | 1.9 | HUF 4T | HUF 20,633.29 | 4.99% up | 11% up | ||
| 38 | PfizerPFE · Health Care | 1.8 | HUF 53.72T | HUF 9,424.88 | 1.44% down | 14% up | ||
| 39 | ViatrisVTRS · Health Care | 1.7 | HUF 7.81T | HUF 6,811.71 | 0.83% down | 96% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Sums are converted from US dollars at today's exchange rate (1 USD = 335.9 HUF). 22 companies have no P/B ratio on file and are not ranked here.
Questions and answers
Which pharmaceutical companies rank first by P/B ratio?
Travere Therapeutics (213), Arrowhead Pharmaceuticals (121) and Rhythm Pharmaceuticals (93.8) are the top three of the 39 pharmaceutical companies ranked by P/B ratio as of 19 Nov 2026, 01:27 UTC.
How many pharmaceutical companies are in this ranking?
39 are ranked by P/B ratio. 22 more have no P/B ratio on file and are left out rather than ranked at zero.
What are these pharmaceutical companies worth together?
The 39 pharmaceutical companies ranked by P/B ratio have a combined market value of HUF 1699.24T as of 19 Nov 2026, 01:27 UTC.
What does ranking by P/B ratio measure?
Share price divided by book value per share: what the market pays for each dollar of shareholders' equity on the balance sheet.
Learn how this ranking works
All markets guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- Piotroski F-score: the nine tests and what they show
The Piotroski F-score is a 0–9 count of simple accounting tests a company passes: four on profitability, three on debt, liquidity and share issuance, two on operating efficiency. Joseph Piotroski's 2000 paper found that among cheap, high book-to-market stocks, high scorers went on to beat low scorers. It is a screen of financial health, not a valuation.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Pharmaceutical companies by P/B ratio”, data as of 19 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?by=pb-ratio
Underlying data: Yahoo Finance; SEC EDGAR.